Effect of triptorelin 3.75 mg subcutaneously injection every 6 weeks on adult height in girls with idiopathic central precocious puberty

Methods Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously injection in our hospital from 2002 to December 2010 and reached final height were collected. These patients were divided into two groups according to whether there was presence of growth deceleration and rhGH used concomitantly during the treatment. Group A: triptorelin alone, n=17; group B: triptorelin + rhGH, n=23. During the treatment, height, weight, annual GV, sexual development, PAH and adverse effects were observed. BA and height SDS were monitored yearly. After discontinuation of treatment, follow-up was continued for 4~9 years till final height was attained, and age of menarche, time of menarche from discontinuation were recorded.